6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)-

Request For Quotation
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Basic information
Product Name:6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)-
Synonyms:6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)-
CAS:2614417-90-0
MF:C32H28ClN7O2S
MW:610.13
EINECS:
Product Categories:
Mol File:2614417-90-0.mol
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Structure
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Chemical Properties
density 1.44±0.1 g/cm3(Predicted)
storage temp. 2-8°C
solubility DMF: 20 mg/ml; DMSO: 10 mg/ml
form A crystalline solid
pka13.20±0.70(Predicted)
color white to beige
InChIKeyGGZYNJKDGRBRKG-SANMLTNESA-N
SMILESCC1=C(C)SC2=C1C(C3=CC=C(C=C3)Cl)=N[C@@H](CC(NC4=CC=C(C=C4)C(NC5=C(C=CC=C5)N)=O)=O)C6=NN=C(C)N26
Safety Information
WGK Germany WGK 3
Storage Class11 - Combustible Solids
MSDS Information
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Usage And Synthesis
DescriptionTW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 μM, respectively).1 It is selective for BD2 over BD1 in BRD4 (IC50 = 0.72 μM) and for HDAC1 over HDAC2 (IC50 = 2.5 μM). TW9 (50 nM) induces apoptosis in, and inhibits proliferation of, MIA PaCa-2 pancreatic cancer cells. It induces cell cycle arrest at the G1 phase in HPAC pancreatic cancer cells when used at a concentration of 2 μM. TW9 acts synergistically with gemcitabine to reduce the viability of HPAC cells.
UsesTW9 is a potent dual inhibitor simultaneously targeting BET and HDAC proteins with KDs of 0.069 μM, 0.231 μM for BRD4(1), BRD4(2), and an IC50 of 0.29 μM for HDAC1, respectively. TW9 is a newly generated adduct of the BET inhibitor (+)-JQ1 (HY-13030) and class I HDAC inhibitor CI994 (HY-50934). TW9 shows high potency in suppressing tumor growth in pancreatic ductal adenocarcinoma (PDAC). TW9 improves the efficacy of the chemotherapeutic agent Gemcitabine (HY-17026)[1].
IC 50BRD4(1): 0.069 μM (Kd); BRD4(2): 0.231 μM (Kd); HDAC1: 0.29 μM (IC50)
References1. Zhang, X., Zegar, T., Weiser, T., et al. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma Int. J. Cancer 147(10),2847-2861(2020).
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Preparation Products And Raw materials
Tag:6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)-(2614417-90-0) Related Product Information
ABBV-075 Hexanamide, 6-[4-(1,4,5,6,7,8-hexahydro-7-methyl-4-oxopyrido[4',3':4,5]thieno[2,3-d]pyrimidin-2-yl)-2,6-dimethylphenoxy]-N-hydroxy- OTX015 AR-42 I-BET151 (GSK1210151A) AU-15330